$265.12−2.21%Close 13 Nov 2026 · Market value $43.51B
About IQVIA
IQVIA is a global provider of clinical research services, commercial insights and healthcare intelligence to life sciences and healthcare organizations. Its offerings span three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Products include cloud-based commercial and clinical applications, real-world evidence services, market information and reference databases, and clinical trial services such as site management, monitoring, and central laboratory support. Clients include biopharmaceutical, biotechnology, medical device and diagnostic companies, along with payers, government agencies, providers, and pharmacies. IQVIA employs approximately 93,000 people and operates in over 100 countries.
A summary of the business section of the company's latest annual report, filed 17 Feb 2026.
Company facts
| Ticker | IQV · NYSE |
|---|
| Sector | Biotechnology |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1478242 |
|---|
| Latest annual report | 10-K, filed 17 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| John M. Leonard, M.D. | Director | 15.4K · < 1% | Grant or award, 23 Apr 2026 |
|---|
| Berkshire James G. | See Remarks | — | Disposition to the issuer, 2 Sep 2026 |
|---|
| STAUB W RICHARD | See Remarks | — | Open-market sale, 3 Aug 2026 |
|---|
| Patel Bhavik | See Remarks | — | Open-market sale, 31 Jul 2026 |
|---|
| Sherbet Eric | See Remarks | — | Open-market sale, 29 Jul 2026 |
|---|
| Cherofsky Keriann | See Remarks | — | Open-market sale, 29 Jul 2026 |
|---|
| BOUSBIB ARI | See Remarks · Director | — | Disposition to the issuer, 29 Jul 2026 |
|---|
| GOGGINS COLLEEN A | Director | — | Grant or award, 23 Apr 2026 |
|---|
| DANHAKL JOHN G | Director | — | Grant or award, 23 Apr 2026 |
|---|
| Burt Carol | Director | — | Grant or award, 23 Apr 2026 |
|---|
| Haas Bernd | See Remarks | — | Shares withheld for tax, 13 Feb 2026 |
|---|
| Fedock Michael J. | See Remarks | — | Shares withheld for tax, 13 Feb 2026 |
|---|
| Grenfell Alistair | See Remarks | — | Shares withheld for tax, 8 Feb 2026 |
|---|
| Bruehlman Ronald E | See Remarks | — | Grant or award, 8 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
IQV in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.